About

Claudio Ricci is a leading figure in the field of hepatopancreatobiliary surgery, with a primary research focus on the oncological safety and comparative effectiveness of minimally invasive techniques for pancreatic cancer. His major contributions center on high-impact, multicenter trials and systematic reviews that rigorously compare open, laparoscopic, and robotic approaches for distal pancreatectomy and pancreaticoduodenectomy. As a key investigator in the landmark DIPLOMA trial (2017, 280 citations) and its subsequent international randomized non-inferiority trial (2023, 121 citations), Ricci has provided crucial evidence on oncological outcomes for minimally invasive distal pancreatectomy in pancreatic ductal adenocarcinoma. His work also extends to cost-effectiveness and quality-of-life analyses (2020, 67 citations), as well as benchmarking studies (2022, 29 citations) that define best achievable outcomes. With over 800 total citations across his most-cited papers, Ricci’s research has shaped clinical guidelines and surgical decision-making. His comprehensive network meta-analyses and systematic reviews, including a 2025 meta-analysis of randomized controlled trials on minimally invasive pancreatoduodenectomy, continue to push the boundaries of evidence-based surgery.

Research Focus

Key Achievements

8
H-Index
10
Papers
780
Total Citations
78
Avg Citations/Paper
🏆 Most Cited Paper
Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA)
280 citations · 2017
📈 Most Prolific Year: 2017 (2 Papers)
🤝 Key Collaborators: 211
🏛 Institutions: Virginia Mason Medical Center, University of Bologna, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Azienda USL di Bologna

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago